Novartis gains FDA nod for Odomzo
This article was originally published in Scrip
Executive Summary
Novartis won US approval on 24 July from the FDA to market Odomzo (sonidegib), previously known as LDE225, as a treatment for adults with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.